Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Pant on Choosing Therapy for Frontline and Beyond in Pancreatic Cancer

April 3rd 2020

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Abou-Alfa Highlights Pending Approvals, Sequencing Concerns, and Future Directions in HCC

April 3rd 2020

Ghassan K. Abou-Alfa, MD, discusses the most intriguing updates in hepatocellular carcinoma, anticipated sequencing challenges, and novel modalities on the horizon.

Debate Continues on Optimal Neoadjuvant Regimen in Resectable Pancreatic Cancer

April 2nd 2020

Michael A. Choti, MD, MBA, FACS, discusses the role of radiation therapy in neoadjuvant therapy for resectable pancreatic cancer, the many benefits of neoadjuvant therapy over up-front surgery, and minimally invasive surgical procedures that are coming to the forefront in this disease.

Pembrolizumab Improves PFS in Frontline MSI-H/dMMR Colorectal Cancer

April 2nd 2020

Frontline pembrolizumab significantly improved progression-free survival versus chemotherapy in patients with microsatellite instability–high or mismatch repair deficient unresectable or metastatic colorectal cancer.

Dr. Kaseb on Research With Targeted Therapy in HCC

April 2nd 2020

Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).

Dr. Raghav on Ongoing Research With Immunotherapy and Targeted Therapy in CRC

April 2nd 2020

Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).

Novel Approaches to Build on Checkpoint Inhibition in GI Cancers

April 1st 2020

Despite some success stories, most gastrointestinal cancers do not respond to single-agent, or even double-agent, immune checkpoint inhibition, Neeha Zaidi, MD, said in a presentation during the 5th Annual School of Gastrointestinal Oncology™ (SOGO®) conference.

Marshall Reflects on Major Advances in mCRC

April 1st 2020

John L. Marshall, MD, reflects on recent advances in the field of metastatic colorectal cancer and discusses ongoing research efforts in the space.

Shah Highlights Shift Toward Earlier Use of IO and Targeted Therapy in Gastric/GEJ Cancer

April 1st 2020

Manish A. Shah, MD, discusses how the management of patients with gastric/GEJ cancer has evolved over the last several years.

Immunotherapy Biomarker Testing Depends on Tumor Type

April 1st 2020

A Working Group of the European Society for Medical Oncology has determined that a decision tree on the sequential use of different tests in immunotherapy decision-making cannot be a general one for all cancers but should be designed on the basis of the specific tumor type.

Dr. Singal on Systemic Therapies in HCC

April 1st 2020

Amit G. Singal, MD, discusses systemic therapies in hepatocellular carcinoma.

Targeted Agents Show Promise in Cholangiocarcinoma

March 31st 2020

Cholangiocarcinoma is both rare and aggressive, and the current systemic standard of care, gemcitabine plus cisplatin, produces only modest results.

Management, Etiology of Younger Patients With CRC Require Deeper Understanding

March 31st 2020

The etiology and overall management of patients with early-onset colorectal cancer needs to be better understood and personalized, respectively, explained Andrea Cercek, MD, in a presentation during the 5th Annual School of Gastrointestinal Oncology™.

Dr. Overman on Choosing Between Regorafenib and TAS-102 in CRC

March 28th 2020

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Dr. Nelson on the CheckMate-142 Trial in MSI-H/dMMR mCRC

March 27th 2020

Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.

Dr. Mizrahi on Optimal Sequencing in BRAF V600E-Mutant mCRC

March 26th 2020

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRC

March 26th 2020

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Dr. Nelson on QOL Data From the BEACON CRC Trial in mCRC

March 26th 2020

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

FLASCO Faculty Flesh Out Case Studies in GI Cancers

March 25th 2020

Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.

Dr. Le on the Need for Aggressive Treatment Interventions in Oligometastatic CRC

March 25th 2020

Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.

NEXT PAGE
PREVIOUS PAGE